Xeljanz (tofacitinib) is a medication prescribed to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The Food and Drug Administration (FDA) recently issued a safety communication warning that the initial results of a safety clinical trial found an increased risk of heart-related problems and cancer in patients taking Xeljanz.
If you or a loved one has suffered a heart-related injury or been diagnosed with cancer after taking Xeljanz, contact our Defective Drug Lawyers today to discuss your potential Xeljanz lawsuit. Our team has over 35 years of experience representing victims harmed by the manufacturers of dangerous drugs. Allow us to deliver the Gold standard of advocacy you deserve for your potential Xeljanz lawsuit.Call 800-903-1643 >
Case Quick Facts
On February 4, 2021, the FDA alerted the public that initial results from a safety clinical trial show that rheumatoid arthritis patients taking Xeljanz were at higher risk of heart-related problems and cancer than patients taking another type of medication used to treat rheumatoid arthritis. The trial compared patients taking the 5 mg and 10 mg twice daily doses of Xeljanz to patients taking a tumor necrosis factor (TNF) inhibitor. Patients participating in the trial were over age 50 and had at least one cardiovascular risk factor. The trial did not include patients taking Xeljanz for ulcerative colitis or psoriatic arthritis.
The initial results found a higher incidence of serious heart issues and cancer in patients taking Xeljanz compared to patients taking the TNF inhibitor. Full results from the trial are not yet available. The FDA is recommending that patients continue taking Xeljanz as prescribed and consult their healthcare providers with questions or concerns. The agency has asked patients and healthcare providers to report side effects involving Xelajnz to its MedWatch program.
In July 2019, the FDA issued a Black Box Warning for Xeljanz after the ongoing safety clinical trial showed an increased risk of blood clots and death in patients taking the 10 mg twice daily dose compared to patients taking the 5 mg twice daily dose or a TNF inhibitor. At that time, patients taking the 10 mg dose in the trial were switched to the 5 mg dose.
The FDA’s safety clinical trial found an increased risk of serious heart-related problems and cancer in patients taking Xeljanz to treat rheumatoid arthritis. Injuries that may be linked to Xeljanz include:
- Heart Attacks
- Pulmonary Embolisms
Xeljanz was approved by the FDA in 2012 to treat adults with rheumatoid arthritis who did not have success treating with methotrexate. The medication was later approved for the treatment of psoriatic arthritis in 2017 and ulcerative colitis in 2018. Xeljanz is manufactured by Pfizer, Inc. and is approved for use in treating rheumatoid arthritis in over 80 countries.
GoldenbergLaw is currently investigating potential Xeljanz lawsuit cases where an individual has taken Xeljanz and suffered a heart-related injury or been diagnosed with cancer. We have successfully represented the victims of defective pharmaceutical drugs for over 35 years. Contact us today for a free Xeljanz lawsuit consultation, and leave the sleepless nights to us.Do I Qualify?
If you or a loved one has suffered a heart-related injury or has been diagnosed with cancer after taking Xeljanz, contact GoldenbergLaw today. Our team of Defective Pharmaceutical Lawyers has successfully helped thousands of clients around the country harmed by defective medications obtain the compensation they deserved. Let us deliver the Gold standard of advocacy you deserve by investigating your potential Xeljanz lawsuit. Call us today for a free Xeljanz lawsuit consultation.Contact Us Call 800-903-1643
Xeljanz Lawsuit FAQs
If you or a loved one has taken Xeljanz and been diagnosed with a heart-related injury or cancer, you may have a case against the manufacturers. Contact GoldenbergLaw today for a free case evaluation.
The FDA recommends that patients currently taking Xeljanz speak with their healthcare providers before making any changes. The agency warns that patients who stop taking Xeljanz without first consulting their providers may worsen their condition.
The FDA’s safety clinical trial of Xeljanz recently concluded. Initial results show that patients taking Xeljanz are at a higher risk of experiencing heart-related problems or developing cancer than patients taking a TNF inhibitor. Final results of the study have not been released. The FDA has announced it will communicate its final recommendations once it has completed its review of the study.
If you or a loved one has been diagnosed with cancer or a heart-related injury after taking Xeljanz, you may be entitled to compensation for your injuries. Contact GoldenbergLaw for a free Xeljanz lawsuit consultation and to learn more about the Xeljanz litigation.
Why Choose GoldenbergLaw?
Our team of Xeljanz attorneys has the experience and expertise required to successfully litigate your claim. We have over 35 years of experience representing victims harmed by defective medications like Xeljanz, let us deliver the Gold standard of advocacy you deserve.
Thousands of Successful Settlements
Comprehensive Knowledge of Complex Issues
Focused on Client-Centered Solutions
Meet Your Xeljanz Team
Have a potential client we could help?
Call us. You’ll sleep better.